

# Delia D'Avola

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2829507/publications.pdf>

Version: 2024-02-01

58  
papers

2,453  
citations

257357

24  
h-index

206029

48  
g-index

60  
all docs

60  
docs citations

60  
times ranked

3799  
citing authors

#	ARTICLE	IF	CITATIONS
1	Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer. <i>Gut</i> , 2022, 71, 2069-2080.	6.1	24
2	The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 76, 1185-1198.	1.8	35
3	Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. <i>Oncogene</i> , 2021, 40, 140-151.	2.6	77
4	Experimental Models of Liquid Biopsy in Hepatocellular Carcinoma Reveal Clone-Dependent Release of Circulating Tumor DNA. <i>Hepatology Communications</i> , 2021, 5, 1095-1105.	2.0	7
5	Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma. <i>PLoS Genetics</i> , 2021, 17, e1009589.	1.5	15
6	Brain ventricular enlargement in human and murine acute intermittent porphyria. <i>Human Molecular Genetics</i> , 2020, 29, 3211-3223.	1.4	3
7	The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1165-1172.	0.9	6
8	Intratumoral heterogeneity and clonal evolution in liver cancer. <i>Nature Communications</i> , 2020, 11, 291.	5.8	230
9	A phenotypical map of disseminated hepatocellular carcinoma suggests clonal constraints in metastatic sites. <i>Histopathology</i> , 2019, 74, 718-730.	1.6	9
10	Hepatocellular Carcinoma: Essentials Interventional Radiologists Need to Know. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1262-1270.	0.9	2
11	GS-14-ENVISION, a phase 3 study to evaluate efficacy and safety of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1, in acute hepatic porphyria patients. <i>Journal of Hepatology</i> , 2019, 70, e81-e82.	1.8	10
12	Abstract 402: RNA-sequencing of plasma exosomes reveals specific transcriptomic profiles in patients with hepatocellular carcinoma. , 2019, , .		0
13	A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. <i>Oncogene</i> , 2018, 37, 3740-3752.	2.6	89
14	High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma. <i>Scientific Reports</i> , 2018, 8, 11570.	1.6	64
15	Abstract 1189: Deciphering the impact of immune editing on liver cancer clonal evolution using immunogenomics. <i>Cancer Research</i> , 2018, 78, 1189-1189.	0.4	1
16	Phase 1&#2 pilot clinical trial in patients with decompensated liver cirrhosis treated with bone marrow-derived endothelial progenitor cells. <i>Translational Research</i> , 2017, 188, 80-91.e2.	2.2	28
17	Cardiovascular morbidity and mortality after liver transplantation: The protective role of mycophenolate mofetil. <i>Liver Transplantation</i> , 2017, 23, 498-509.	1.3	51
18	Immune Checkpoint Inhibitors for the Treatment of Hepatocellular Carcinoma. , 2017, , 51-68.		0

#	ARTICLE	IF	CITATIONS
19	Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation. <i>Annals of Transplantation</i> , 2017, 22, 141-147.	0.5	20
20	NatB-mediated protein N-terminal acetylation is a potential therapeutic target in hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 40967-40981.	0.8	29
21	Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2017, , 25-43.	0.1	0
22	Abstract 4393: Integrative molecular analysis of gene expression and methylation reveals 116 putative key regulator genes of human hepatocarcinogenesis. , 2017, , .		0
23	Controlling Diabetes After Liver Transplantation. <i>Transplantation</i> , 2016, 100, e66-e73.	0.5	15
24	Natural history of nonalcoholic steatohepatitis/nonalcoholic fatty liver disease and hepatocellular carcinoma: Magnitude of the problem from a hepatology clinic perspective. <i>Clinical Liver Disease</i> , 2016, 8, 100-104.	1.0	20
25	Factors related to increased resting energy expenditure in men with liver cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 139-145.	0.8	25
26	Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. <i>Journal of Hepatology</i> , 2016, 65, 776-783.	1.8	119
27	Prospect and progress of gene therapy in acute intermittent porphyria. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 711-717.	0.5	2
28	Recombinant AAV Integration Is Not Associated With Hepatic Genotoxicity in Nonhuman Primates and Patients. <i>Molecular Therapy</i> , 2016, 24, 1100-1105.	3.7	122
29	Abstract 2383: Multiregional RNA sequencing identifies intratumor transcriptomic heterogeneity in a subset of early-stage hepatocellular carcinoma. , 2016, , .		0
30	Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection. <i>Molecular Therapy - Methods and Clinical Development</i> , 2015, 2, 15006.	1.8	15
31	Immune monitoring of immunosuppression withdrawal of liver transplant recipients. <i>Transplant Immunology</i> , 2015, 33, 110-116.	0.6	25
32	Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation. <i>Liver International</i> , 2015, 35, 1590-1596.	1.9	55
33	Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. <i>Liver International</i> , 2015, 35, 1715-1721.	1.9	132
34	V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante. <i>Cirugía Española</i> , 2015, 93, 619-637.	0.1	3
35	Is Liver Biopsy Necessary in the Evaluation of a Living Donor for Liver Transplantation?. <i>Transplantation Proceedings</i> , 2014, 46, 3082-3083.	0.3	6
36	Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension. <i>Hpb</i> , 2014, 16, 243-249.	0.1	69

#	ARTICLE	IF	CITATIONS
37	Trial of complete weaning from immunosuppression for liver transplant recipients: Factors predictive of tolerance. <i>Liver Transplantation</i> , 2013, 19, 937-944.	1.3	87
38	Safety and Liver Transduction Efficacy of rAAV5-cohPBGD in Nonhuman Primates: A Potential Therapy for Acute Intermittent Porphyria. <i>Human Gene Therapy</i> , 2013, 24, 1007-1017.	1.4	50
39	Prognostic factors and prevention of radioembolization-induced liver disease. <i>Hepatology</i> , 2013, 57, 1078-1087.	3.6	240
40	Lung cancer screening with low-radiation dose computed tomography after liver transplantation. <i>Annals of Transplantation</i> , 2013, 18, 587-592.	0.5	11
41	Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. <i>European Journal of Surgical Oncology</i> , 2012, 38, 594-601.	0.5	122
42	Subsequent Nonmelanoma Skin Cancer after Liver Transplantation. <i>Transplantation Proceedings</i> , 2012, 44, 1568-1570.	0.3	13
43	Efficacy of Transjugular Intrahepatic Portosystemic Shunt to Prevent Total Portal Vein Thrombosis in Cirrhotic Patients Awaiting for Liver Transplantation. <i>Transplantation Proceedings</i> , 2012, 44, 2603-2605.	0.3	39
44	Angiogenic Cytokines in Patients Undergoing Antiviral Treatment for Chronic Hepatitis C Virus Infection. <i>Journal of Interferon and Cytokine Research</i> , 2011, 31, 207-210.	0.5	7
45	Treatment of murine fulminant hepatitis with genetically engineered endothelial progenitor cells. <i>Journal of Hepatology</i> , 2011, 55, 828-837.	1.8	14
46	Applicability of Living Donor Liver Transplantation in a Program of Adult Liver Transplantation. <i>Transplantation Proceedings</i> , 2011, 43, 690-691.	0.3	2
47	Prognosis of Hepatocellular Carcinoma in Relation to Treatment Across BCLC Stages. <i>Annals of Surgical Oncology</i> , 2011, 18, 1964-1971.	0.7	53
48	Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: The effect of smoking withdrawal. <i>Liver Transplantation</i> , 2011, 17, 402-408.	1.3	89
49	Transarterial therapies for hepatocellular carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1057-1073.	0.9	32
50	Prophylaxis and treatment of hepatitis B infection in the setting of liver transplantation. <i>Revista Espanola De Enfermedades Digestivas</i> , 2011, 103, 142-9.	0.1	3
51	Analysis of Prognostic Factors After Yttrium-90 Radioembolization of Advanced Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1441-1448.	0.4	54
52	Radioembolization with Use of Yttrium-90 Resin Microspheres in Patients with Hepatocellular Carcinoma and Portal Vein Thrombosis. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 1205-1212.	0.2	136
53	A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma. <i>Hepato-Gastroenterology</i> , 2009, 56, 1683-8.	0.5	33
54	Lower schooling, higher hepatitis C virus prevalence in Italy: An association dependent on age. <i>Journal of Clinical Virology</i> , 2007, 40, 168-170.	1.6	4

#	ARTICLE	IF	CITATIONS
55	Frequency of diabetes and thyroid autoantibodies in patients with autoimmune endocrine disease from Cameroon. <i>Clinical Immunology</i> , 2006, 118, 229-232.	1.4	21
56	Subcellular shift of the hepatic growth hormone receptor with progression of hepatitis C virus-related chronic liver disease. <i>Histopathology</i> , 2006, 48, 822-830.	1.6	6
57	Diabetes in chronic liver disease: from old concepts to new evidence. <i>Diabetes/Metabolism Research and Reviews</i> , 2006, 22, 274-283.	1.7	94
58	The Role of Ribavirin in the Combination Therapy of Hepatitis C Virus Infection. <i>Current Pharmaceutical Design</i> , 2004, 10, 2081-2092.	0.9	23